Clinical efficacy of cerivastatin: Phase IIa dose-ranging and dose- scheduling studies

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 26J-31J

  Hunninghake, Donald B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032572793     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00434-2     Document Type: Conference Paper

References (17)

1. Angerbauer R., Bischoff H., Steinke W., Ritter X. BAY w 6228. Hypolipidemic HMG-CoA reductase inhibitor. Drugs Fut. 19:1994;537-541.
2. Bischoff H., Angerbauer R., Bender J., Bischoff E., Fagiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.
3. Stein E.A., Sprecher D., Allenby K.S., Tosiello R.L., Whalen E., Ripa S. Cerivastatin, a new potent HMG-CoA reductase inhibitor efficacy and tolerability in primary hypercholesterolemia . J Cardiovasc Pharmacol Ther. 2:1997;7-16.
4. Mazzu A.L., Lettieri J., Kaiser L., Frey R., Heller A.H. Ascending multiple dose safety, tolerability and pharmacodynamics of rivastatin in humans. (Abstr. No. PIII-95) Clin Pharmacol Ther. 53:1993;230.
5. Lettieri J., Krol G., Mazzu A.L., Shah A., Falk R., Beck C. Effect of age and gender on the steady-state pharmacokinetics of rivastatin. (Abstr. No. PPDM 8159) Pharm Res. 10:(suppl):1993;S338.
6. Vormfelde S., Freundenthaler S., Mück W., Heyen P., Schmage N., Kuhlmann J., Gundert-Remy U., Gleiter C.H. Pharmacokinetics of cerivastatin in subjects with normal and impaired renal function. Br J Clin Pharmacol. 45:1998;583-590.
7. Schall R., Müller F.O., Hundt H.K.L., Ritter W., Duursema L., Groenewoud G., Middle M.V. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol. 35:1995;306-313.
8. Lettieri J, Krol G, Mazzu AL, Fiebach M, Heller AH. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Abstract at the 68th Meeting of the European Atherosclerosis Society (EAS) in Brugge/Belgium, May 7-10, 1997.
9. Mück W., Ritter W., Dietrich H., Frey R., Kuhlmann J. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;261-264.
10. Mück W., Ochmann K., Unger S., Kuhlmann J. Influence of erythromycin pre-and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Clin Pharmacol Ther. 53:1998;469-473.
11. Duggan D.E., Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev. 22:1990;333-362.
12. Hsu I., Spinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 29:1995;743-759.
13. Illingworth D.R., Tobert J.A. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 16:1994;366-385.
14. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
15. Parker T.S., McNamara D.J., Brown C., Garrigan O., Kolb R., Batwin H., Ahrens E.H. Jr. Mevalonic acid in human plasma relationship of concentration and circadian rhythm to cholesterol synthesis rates in man . Proc Natl Acad Sci USA. 79:1982;3037-3041.
16. Illingworth D.R. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther. 40:1986;338-343.
17. Saito Y., Yoshida S., Nakaya N., Hata Y., Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Throm. 11:1991;816-826.